Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)-Reference-Cited by-同舟云学术

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

Published:2016-01-06 Issue:1 Volume:18 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

de Groot Stefanie, ,Charehbili Ayoub,van Laarhoven Hanneke W. M.,Mooyaart Antien L.,Dekker-Ensink N. Geeske,van de Ven Saskia,Janssen Laura G. M.,Swen Jesse J.,Smit Vincent T. H. B. M.,Heijns Joan B.,Kessels Lonneke W.,van der Straaten Tahar,Böhringer Stefan,Gelderblom Hans,van der Hoeven Jacobus J. M.,Guchelaar Henk-Jan,Pijl Hanno,Kroep Judith R.

Funder

KWF Kankerbestrijding (NL)

Amgen (US)

Novartis (CH)

Sanofi Aventis

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-015-0663-3.pdf

Reference45 articles.

1. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47.

2. Renehan AG, Zwahlen M, Minder C, O’dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.